Department of Pediatric Cardiology and Congenital Heart Diseases, German Heart Center Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Clinic for Pediatric Cardiology and Congenital Heart Defects, Herz- Und Diabeteszentrum NRW, Ruhr University of Bochum, Georgstraße 11, 32545, Bad Oeynhausen, Germany.
Pediatr Cardiol. 2021 Jan;42(1):78-88. doi: 10.1007/s00246-020-02456-2. Epub 2020 Oct 3.
Interventional closure of congenital ventricular septal defects (VSD) is recording a continuous rise in acceptance. Complete atrioventricular block (cAVB) and residual shunting are major concerns during follow-up, but long-term data for both are still limited. We retrospectively evaluated the outcome of patients with interventional VSD closure and focused on long-term results (> 1 year follow-up). Transcatheter VSD closures were performed between 1993 and 2015, in 149 patients requiring 155 procedures (104 perimembranous, 29 muscular, 19 residual post-surgical VSDs, and 3 with multiple defects). The following devices were used: 65 × Amplatzer™ Membranous VSD Occluder, 33 × Duct Occluder II, 27 × Muscular VSD Occluder, 3 × Duct Occluder I, 24 × PFM-Nit-Occlud®, and 3 × Rashkind-Occluder. The median age at time of implantation was 6.2 (0.01-66.1) years, median height 117 (49-188) cm, and median weight 20.9 (3.2-117) kg. Median follow-up time was 6.2 (1.1-21.3) years and closure rate was 86.2% at last follow-up. Complications resulting in device explantation include one case of cAVB with a Membranous VSD occluder 7 days after implantation and four cases due to residual shunt/malposition. Six (4%) deaths occurred during follow-up with only one procedural related death from a hybrid VSD closure. Overall, our reported results of interventional VSD closure show favorable outcomes with only one (0.7%) episode of cAVB. Interventional closure offers a good alternative to surgical closure and shows improved performance by using softer devices. However, prospective long-term data in the current era with different devices are still mandatory to assess the effectiveness and safety of this procedure.
介入治疗先天性室间隔缺损(VSD)的接受度不断提高。完全性房室传导阻滞(cAVB)和残余分流是随访期间的主要关注点,但两者的长期数据仍有限。我们回顾性评估了介入 VSD 封堵患者的结局,并重点关注了>1 年的随访结果。1993 年至 2015 年间,在 149 例需要 155 次手术的患者中进行了经导管 VSD 封堵术(104 例为膜周部,29 例为肌部,19 例为残余术后 VSD,3 例为多发缺损)。使用了以下器械:65×Amplatzer™Membranous VSD Occluder、33×Duct Occluder II、27×Muscular VSD Occluder、3×Duct Occluder I、24×PFM-Nit-Occlud®和 3×Rashkind-Occluder。植入时的中位年龄为 6.2(0.01-66.1)岁,中位身高 117(49-188)cm,中位体重 20.9(3.2-117)kg。中位随访时间为 6.2(1.1-21.3)年,末次随访时的封堵率为 86.2%。导致器械取出的并发症包括 1 例植入后 7 天发生的膜周部 VSD 封堵器引起的 cAVB 和 4 例因残余分流/错位引起的病例。随访期间发生 6 例(4%)死亡,仅有 1 例因杂交 VSD 封堵术相关死亡。总体而言,我们报道的介入 VSD 封堵结果显示,只有 1 例(0.7%)发生 cAVB。介入封堵为外科封堵提供了一种较好的替代方法,并且使用较软的器械可提高性能。然而,在当前时代,使用不同的器械进行前瞻性长期数据评估仍然是必要的,以评估该手术的有效性和安全性。